The DOI matches its Crossref record, with a small difference in title or year; 24 of the 24 references it cites were found in a registry or an index.
Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials
Open accessAbstract
IMPORTANCE: Metastatic colorectal cancer (mCRC) is heterogeneous, and primary tumors arising from different regions of the colon are clinically and molecularly distinct. OBJECTIVE: To examine the prognostic and predictive value of primary tumor location in patients with RAS wild-type (wt) mCRC treated with first-line fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab in the Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) trial and FOLFIRI Plus Cetuximab Versus FOLFIRI Plus Bevacizumab as First-Line Treatment For Patients With Metastatic Colorectal Cancer (FIRE-3) trial. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective analysis patients with RAS wt metastatic colorectal cancer from the CRYSTAL and FIRE-3 trials were classified as having left-sided or right-sided mCRC, defined, respectively, as patients whose tumors originated in the splenic flexure, descending colon, sigmoid colon, or rectum vs appendix, cecum, ascending colon, hepatic flexure, or transverse colon. MAIN OUTCOMES AND MEASURES: Progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were assessed according to tumor location and treatment arm. RESULTS: In the RAS wt populations of the CRYSTAL and FIRE-3 trials, patients with left-sided tumors (n = 142 and n = 157, respectively) had markedly superior PFS, OS, and ORR compared with patients with right-sided tumors (n = 33 and n = 38, respectively). Among CRYSTAL and FIRE-3 study patients with RAS wt left-sided tumors, FOLFIRI plus cetuximab significantly improved OS relative to the respective comparators (FOLFIRI and FOLFIRI plus bevacizumab); in contrast, in RAS wt patients with poor-prognosis right-sided tumors, limited efficacy benefits were observed upon the addition of cetuximab to FOLFIRI in CRYSTAL, and comparable outcomes were observed between the FOLFIRI plus cetuximab and FOLFIRI plus bevacizumab arms of FIRE-3. A significant interaction was observed between primary tumor location and treatment for OS (CRYSTAL: hazard ratio [HR], 1.95; 95% CI, 1.09-3.48 and FIRE-3: HR, 0.40; 95% CI, 0.23-0.70) within the RAS wt populations of both studies in multivariable models that also included sex, prior adjuvant therapy, and BRAF mutational status. CONCLUSIONS AND RELEVANCE: In the RAS wt populations of CRYSTAL and FIRE-3, patients with left-sided tumors had a markedly better prognosis than those with right-sided tumors. First-line FOLFIRI plus cetuximab clearly benefitted patients with left-sided tumors (vs FOLFIRI or FOLFIRI plus bevacizumab, respectively), whereas patients with right-sided tumors derived limited benefit from standard treatments. TRIAL REGISTRATION: clinicaltrials.gov Identifiers: CRYSTAL, NCT00154102, and FIRE-3, NCT00433927.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“bevacizumab is effective regardless of RAS gene status”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Self-citationCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Self-citationVan Cutsem, E., Köhne, C.-H., Láng, I., Folprecht, G., Nowacki, M. P., Cascinu, S., Shchepotin, I., Maurel, J., Cunningham, D., Tejpar, S., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5091 · Cited by 1,882
Self-citationHeinemann, V., von Weikersthal, L. F., Decker, T., Kiani, A., Vehling-Kaiser, U., Al-Batran, S.-E., Heintges, T., Lerchenmüller, C., Kahl, C., Seipelt, G., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70330-4 · Cited by 1,740
Self-citationVan Cutsem, E., Lenz, H.-J., Köhne, C.-H., Heinemann, V., Tejpar, S., Melezínek, I., Beier, F., Stroh, C., Rougier, P., van Krieken, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4812 · Cited by 789
Self-citationPowell, A. E., Wang, Y., Li, Y., Poulin, E. J., Means, A. L., Washington, M. K., Higginbotham, J. N., Juchheim, A., Prasad, N., Levy, S. E., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.042 · Cited by 694
Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features
Missiaglia, E., Jacobs, B., D’Ario, G., Narzo, A. F. D., Soneson, C., Budínská, E., Popovici, V. C., Vecchione, L., Gerster, S., Yan, P., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu275 · Cited by 646
Self-citationPrimary Tumor Location as a Prognostic Factor in Metastatic Colorectal Cancer
Loupakis, F., Yang, D., Yau, L., Feng, S., Cremolini, C., Zhang, W., Maus, M. K. H., Antoniotti, C., Langer, C., Scherer, S. J., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju427 · Cited by 477
Self-citationBrule, S. Y., Jonker, D. J., Karapetis, C. S., O’Callaghan, C. J., Moore, M. J., Wong, R. P. W., Tebbutt, N. C., Underhill, C. R., Yip, D., Zalcberg, J. R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.015 · Cited by 335
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 710
Ketzer, S., Schimmel, K. J. M., Koopman, M., & Guchelaar, H. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0590-9 · Cited by 23
Lee, J., Xiao, Y.-Y., Sun, Y. Y., Balderacchi, J., Clark, B., Desani, J., Kumar, V., Saverimuthu, A., Win, K. T., Huang, Y., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3799-y · Cited by 21
Repurposing EGFR Inhibitor Utility in Colorectal Cancer in Mutant APC and TP53 Subpopulations
Yang, M., Schell, M. J., Loboda, A. P., Nebozhyn, M., Li, J., Teer, J. K., Pledger, W. J., & Yeatman, T. J. (2019) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-18-1383 · Cited by 21
Kotha, N. V., Baumgartner, J. M., Veerapong, J., Cloyd, J. M., Ahmed, A., Grotz, T. E., Leiting, J. L., Fournier, K. F., Lee, A., Dineen, S. P., et al. (2019) · Annals of Surgical Oncology · doi:10.1245/s10434-019-07373-0 · Cited by 21
Turner, M. C., Becerra, D. C., Sun, Z., Watson, J., Leung, K., Migaly, J., Mantyh, C. R., & Blazer, D. G. (2019) · Techniques in Coloproctology · doi:10.1007/s10151-019-01997-w · Cited by 21
Belardinilli, F., Capalbo, C., Malapelle, U., Pisapia, P., Raimondo, D., Milanetti, E., Mahdavian, Y., Liccardi, C., Paci, P., Sibilio, P., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00560 · Cited by 20
Chen, X., Hu, W., Huang, C., Liang, W., Zhang, J., Wu, D., Lv, Z., Li, Y., Luo, Y., Liang, Z., et al. (2020) · International Journal of Surgery · doi:10.1016/j.ijsu.2020.06.024 · Cited by 20
Stintzing, S., Klein‐Scory, S., von Weikersthal, L. F., Fuchs, M., Kaiser, F., Heinrich, K., Modest, D. P., Hofheinz, R., Decker, T. W., Gerger, A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco.24.01174 · Cited by 22
Self-citationZhang, T., He, W., Zi, M.-J., Song, G., Yi, D., & Yang, Y. (2018) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-018-2980-0 · Cited by 20
Azar, I. H., Masalmeh, N. A., Esfandiarifard, S., Virk, G. S., Kiwan, W., Shields, A. F., Mehdi, S. B., & Philip, P. A. (2021) · Cancer Medicine · doi:10.1002/cam4.3757 · Cited by 20
Sato, T., Osumi, H., Shinozaki, E., Ooki, A., Shimozaki, K., Kamiimabeppu, D., Nakayama, I., Wakatsuki, T., Ogura, M., Takahari, D., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15186 · Cited by 20
Dichotomous colorectal cancer behaviour
Aljama, S., Lago, E. P., Zafra, O., Sierra, J., Simón, D., Santos, C., Rodríguez-Pascual, J., & Garcia‐Romero, N. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104067 · Cited by 21
Chebib, R., Verlingue, L., Cozic, N., Faron, M., Burtin, P. C., Boige, V., Hollebecque, A., & Malka, D. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.07.004 · Cited by 21
Is the Location of the Tumor Another Prognostic Factor for Patients With Colon Cancer?
Jung, M.-K., Shin, U. S., Ki, Y.-J., Kim, Y. B., Moon, S. M., & Sung, S.-J. (2017) · Annals of Coloproctology · doi:10.3393/ac.2017.33.6.210 · Cited by 20
Mendis, S. R., Beck, S., Lee, B., Lee, M., Wong, R., Kosmider, S., Shapiro, J. D., Yip, D., Steel, S. A., Nott, L. M., et al. (2019) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.13135 · Cited by 20
Sagawa, T., Sato, Y., Hirakawa, M., Hamaguchi, K., Fukuya, A., Okamoto, K., Miyamoto, H., Muguruma, N., Fujikawa, K., Takahashi, Y., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76756-1 · Cited by 17
Sun, J., Xu, J., Sun, C., Zheng, M., Li, Y., Zhu, S., & Zhang, S. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.568818 · Cited by 19
The Evolving Field of Neoadjuvant Therapy in Locally-advanced Rectal Cancer: Evidence and Prospects
Ominelli, J., Valadão, M., Araújo, R. O., de Melo, A. C., & Araujo, L. H. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.06.005 · Cited by 19
Colorectal cancer during pregnancy or postpartum: Case series and literature review
Rogers, J. E., Woodard, T. L., Nogueras‐González, G. M., Dasari, A. N., Johnson, B., Morris, V. K., Kee, B. K., Vilar, E., You, Y. N., Chang, G. J., et al. (2021) · Obstetric Medicine · doi:10.1177/1753495x211041228 · Cited by 19
Hamfjord, J., Myklebust, T. Å., Larsen, I. K., Kure, E. H., Glimelius, B., Guren, T. K., Tveit, K. M., & Guren, M. G. (2021) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-21-0555 · Cited by 21
Zhang, T., Yang, Y., He, B., Yi, D., Hao, J., & Zhang, D. (2017) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-017-2962-2 · Cited by 19
Peeters, M., Forget, F., Karthaus, M., Valladares‐Ayerbes, M., Zaniboni, A., Demonty, G., Guan, X., & Rivera, F. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000297 · Cited by 19
Tumor location impact in stage II and III colon cancer: epidemiological and outcome evaluation
Mejri, N., Dridi, M., Benna, H. E., Labidi, S., Daoud, N., & Boussen, H. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.12.02 · Cited by 19
Loupakis, F., Hurwitz, H. I., Saltz, L. B., Arnold, D., Grothey, A. F., Nguyen, Q. L., Osborne, S., Talbot, J., Srock, S., & Lenz, H. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0304-6 · Cited by 19
Self-citationRussolillo, N., Sperti, E., Langella, S., Menonna, F., Allieta, A., Maïo, M. D., & Ferrero, A. (2019) · HPB · doi:10.1016/j.hpb.2019.05.014 · Cited by 19
Impact of primary tumour location on colorectal liver metastases: A systematic review
Bingham, G., Shetye, A., Suresh, R., & Mirnezami, R. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i5.294 · Cited by 19
Distinct metastatic patterns in colorectal cancer patients based on primary tumour location
Hugen, N., & Nagtegaal, I. D. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.003 · Cited by 19
Lièvre, A., Ouine, B., Canet, J., Cartier, A., Amar, Y., Cacheux, W., Mariani, O., Guimbaud, R., Selves, J., Lecomte, T., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.353 · Cited by 18
Ouchi, K., Takahashi, S. I., Okita, A., Sakamoto, Y., Muto, O., Amagai, K., Okada, T., Ohori, H., Shinozaki, E., & Ishioka, C. (2021) · Cancer Science · doi:10.1111/cas.15252 · Cited by 17
Liu, L., Ji, J., Ge, X., Ji, Z., Li, J., Wu, J., Zhu, J., Yao, J., Zhu, F., Mao, B., et al. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001295 · Cited by 19
Franchi, M., Barni, S., Tagliabue, G., Ricci, P., Mazzucco, W., Tumino, R., Caputo, A., Corrao, G., & on behalf of the GRETA working group (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0314 · Cited by 18
Primary Tumor Resection for Stage IV Colorectal Cancer in the Era of Targeted Chemotherapy
Shida, D., Boku, N., Tanabe, T., Yoshida, T., Tsukamoto, S., Takashima, A., & Kanemitsu, Y. (2018) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-018-4044-y · Cited by 18
Kennecke, H. F., Berry, S. R., Maroun, J. A., Kavan, P., Aucoin, N., Couture, F., Poulin-Costello, M., & Gillesby, B. (2019) · Current Oncology · doi:10.3747/co.26.4861 · Cited by 18
Seligmann, J. F., Elliott, F., Richman, S. D., Hemmings, G., Brown, S., Jacobs, B., Williams, C. J. M., Tejpar, S., Barrett, J. H., Quirke, P., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.04.476 · Cited by 18
Self-citationSignificance of Radiofrequency Ablation for Unresectable Colorectal Cancer With Liver Metastases
Tago, T., Katsumata, K., Udou, R., Kasahara, K., Mazaki, J., Kuwabara, H., Enomoto, M., Ishizaki, T., Nagakawa, Y., Sugimoto, K., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15367 · Cited by 18
Updates in version 2019 of CSCO guidelines for colorectal cancer from version 2018
Yuan, Y., Wang, X., Chen, G., Wang, Y., Sheng, W., Li, X., Zhou, A., Zhang, Z., Li, G., Cai, S., et al. (2019) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2019.03.03 · Cited by 18
Huemer, F., Thaler, J., Piringer, G., Hackl, H., Pleyer, L., Hufnagl, C., Weiß, L., & Greil, R. (2018) · BMC Cancer · doi:10.1186/s12885-017-3955-4 · Cited by 18
Jensen, C. E., Villanueva, J. Y., & Loaiza‐Bonilla, A. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.06.10 · Cited by 18
Yoon, S. E., Lee, S. J., Lee, J., Park, S. H., Park, J. O., Lim, H. Y., Kang, W. K., Park, Y. S., & Kim, S. T. (2019) · Journal of Cancer · doi:10.7150/jca.29106 · Cited by 18
Primary Tumor Location as a Prognostic and Predictive Marker in Metastatic Colorectal Cancer (mCRC)
Bahl, A., Talwar, V., Sirohi, B., Mehta, P., Arya, D., Shrivastava, G., Dahiya, A., & Pavithran, K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00964 · Cited by 18
Primary Tumor Sidedness Predicts Bevacizumab Benefit in Metastatic Colorectal Cancer Patients
You, X.-H., Wen, C., Xia, Z., Sun, F., Li, Y., Wang, W., Fang, Z., Chen, Q.-G., Zhang, L., Jiang, Y.-H., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00723 · Cited by 17
No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer?
Sunakawa, Y., Tsuji, A., Fujii, M., & Ichikawa, W. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx231 · Cited by 17
Prognostic effect of sidedness in early stage versus advanced colon cancer
Kennecke, H. F., Yin, Y., Davies, J. M., Speers, C. H., Cheung, W. Y., & Lee‐Ying, R. M. (2018) · Health Science Reports · doi:10.1002/hsr2.54 · Cited by 17
Gherman, A., Bălăcescu, L., Cetean, S., Vlad, C. I., Bălăcescu, O., Irimie, A., & Lisencu, C. I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062089 · Cited by 17
Fischer, L. E., Stintzing, S., von Weikersthal, L. F., Modest, D. P., Decker, T. W., Kiani, A., Kaiser, F., Al-Batran, S.-E., Heintges, T., Lerchenmuller, C. A., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01854-y · Cited by 17
Self-citationJoranger, P., Nesbakken, A., Sørbye, H., Hoff, G. S., Oshaug, A., & Aas, E. (2019) · The European Journal of Health Economics · doi:10.1007/s10198-019-01130-6 · Cited by 17
Negative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead
Sundar, R., Tan, I. B. H., & Chee, C. E. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01977 · Cited by 17
Offermans, K., Reitsam, N. G., Simons, C. C. J. M., Grosser, B., Zimmermann, J., Grabsch, H. I., Märkl, B., & van den Brandt, P. A. (2024) · Cancer & Metabolism · doi:10.1186/s40170-024-00349-z · Cited by 17
The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm?
Venturini, J., Massaro, G., Lavacchi, D., Rossini, D., Pillozzi, S., Caliman, E., Pellegrini, E., & Antonuzzo, L. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104515 · Cited by 18
Lee, K.-H., Chen, W.-S., Jiang, J., Yang, S.-H., Wang, H.-S., Chang, S., Lan, Y., Lin, C., Lin, H., Huang, S., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01470-2 · Cited by 16
Waldstein, S., Spengler, M., Pinchuk, I. V., & Yee, N. S. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13071114 · Cited by 20
Karaoğlan, B. B., Öz, D. K., Araz, M., Akyol, C., & Utkan, G. (2024) · Current Oncology Reports · doi:10.1007/s11912-024-01548-z · Cited by 16
Perron, U., Grassi, E., Chatzipli, A., Viviani, M., Karakoç, E., Trastulla, L., Brochier, L. M., Isella, C., Zanella, E. R., Klett, H., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53163-y · Cited by 17
Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt?
Athauda, A., Segelov, E., Ali, Z., & Chau, I. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.12.004 · Cited by 16
Serayssol, C., Maulat, C., Breibach, F., Mokrane, F., Sèlves, J., Guimbaud, R., Otal, P., Suc, B., Bérard, E., & Muscari, F. (2019) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v11.i4.295 · Cited by 16
Impact of Tumor Site on Lymph Node Status and Survival in Colon Cancer
Xie, Y., Huang, Y., Ruan, Q., Wang, H., Liang, X., Hu, Z., & Li, X. (2019) · Journal of Cancer · doi:10.7150/jca.32038 · Cited by 16
Nagai, Y., Kiyomatsu, T., Gohda, Y., Otani, K., Deguchi, K., & Yamada, K. (2021) · Global Health & Medicine · doi:10.35772/ghm.2020.01096 · Cited by 18
Wang, Y., Yang, L., Zhou, M., Shen, L., Zhang, J., Deng, W., Liang, L., Hu, R., Yang, W., Yao, Y., et al. (2018) · Cancer Management and Research · doi:10.2147/cmar.s163302 · Cited by 16
Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants
Post, J. B., Roodhart, J. M. L., & Snippert, H. J. G. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.005 · Cited by 16
de Paula, T. R., Simon, H. L., da Luz, M. M. P., & Keller, D. S. (2020) · Techniques in Coloproctology · doi:10.1007/s10151-020-02329-z · Cited by 16
Molecular genetic classification of colorectal cancer subtypes: current state of the problem
Kit, O. I., Dzhenkova, E. A., Арменовна, М. Э., Gevorkyan, Y. A., Sagakyants, A. B., Тимошкина, Н. Н., Kaymakchi, O. Y., Kaymakchi, D. O., Tolmakh, R. E., Dashkov, A. V., et al. (2021) · South Russian Journal of Cancer · doi:10.37748/2686-9039-2021-2-2-6 · Cited by 16
Yohanathan, L., Chopra, A., Simo, K. A., Clancy, T. E., Khithani, A. S., Anaya, D. A., Maegawa, F. B., Sheikh, M. R., Raoof, M., Jacobs, M. R., et al. (2024) · HPB · doi:10.1016/j.hpb.2024.12.006 · Cited by 16
Cann, C., LaPelusa, M. B., Cimino, S. K., & Eng, C. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1176950 · Cited by 16
Prognostic value of primary tumor location in colorectal cancer: an updated meta-analysis
Gholamalizadeh, H., Zafari, N., Velayati, M., Fiuji, H., Maftooh, M., Ghorbani, E., Hassanian, S. M., Khazaei, M., Ferns, G. A., Nazari, E., et al. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01120-2 · Cited by 15
Roazzi, L., Patelli, G., Bencardino, K. B., Amatu, A., Bonazzina, E. F., Tosi, F., Amoruso, B., Bombelli, A., Mariano, S., Stabile, S., et al. (2024) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2024.02.001 · Cited by 15
Kim, D., Kim, S. Y., Lee, J. S., Hong, Y. S., Kim, J. E., Kim, K., Kim, J., Jang, S. J., Yoon, Y., & Kim, T. W. (2017) · BMC Gastroenterology · doi:10.1186/s12876-017-0694-6 · Cited by 15
Salem, M. E., Yin, J., Weinberg, B. A., Renfro, L. A., Pederson, L., Maughan, T., Adams, R., Cutsem, E. V., Falcone, A., Tebbutt, N. C., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.08.020 · Cited by 15
Self-citationPrimary tumor side is associated with prognosis of colorectal cancer patients with brain metastases
Bergen, E. S., Scherleitner, P., Ferreira, P., Kiesel, B., Müller, C., Widhalm, G., Dieckmann, K. U., Prager, G. W., Preusser, M., & Berghoff, A. S. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100168 · Cited by 14
Song, K., Zhao, W., Wang, W., Zhang, N., Wang, K., & Chang, Z. (2018) · Cancer Science · doi:10.1111/cas.13622 · Cited by 15
Péron, J., Mercier, F., Tuech, J., Younan, R. J., Sidéris, L., Gelli, M., Dumont, F., Roy, B. L., Sgarbura, O. A., Dico, R. L., et al. (2018) · Surgery · doi:10.1016/j.surg.2018.07.027 · Cited by 15
Akce, M., Zakka, K. M., Jiang, R., Williamson, S., Alese, O. B., Shaib, W. L., Wu, C. S.-Y., Behera, M., & El‐Rayes, B. F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.592351 · Cited by 15
Meltzer, S., Bakke, K. M., Rød, K. L., Negård, A., Flatmark, K., Solbakken, A. M., Kristensen, A. T., Fuglestad, A. J., Kersten, C., Dueland, S., et al. (2019) · Clinical and Translational Radiation Oncology · doi:10.1016/j.ctro.2019.11.006 · Cited by 14
Chen, D., Li, L., Zhang, X., Gao, G., Shen, L., Hu, J., Yang, M., Liu, B., & Qian, X. (2018) · Medicine · doi:10.1097/md.0000000000010097 · Cited by 14
Makowiec, F., Menzel, M. M., Bronsert, P., Holzner, P. A., Klock, A., Lang, S. A., Fichtner‐Feigl, S., & Neeff, H. P. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.06.019 · Cited by 14
Zhang, J., Quadri, S. A., Wolfgang, C. L., & Zheng, L. (2018) · Biomedicines · doi:10.3390/biomedicines6030087 · Cited by 15
Benavides, M., Díaz-Rubio, E., Carrato, A., Abad, A., Guillén‐Ponce, C., Garcia-Alfonso, P., Gil, S., Cano, M. T., Safont, M. J., Gravalos, C., et al. (2019) · PubMed Central · doi:10.1136/esmoopen-2019-000599 · Cited by 14
Stintzing, S., van Oostrum, I., Pescott, C. P., Ronga, P., Heeg, B. M. S., & Heinemann, V. (2020) · Journal of Medical Economics · doi:10.1080/13696998.2019.1709848 · Cited by 14
Self-citationHan, J., Xiao, D., Tan, C., Zeng, X., Hu, H., Zeng, S., Jiang, Q., She, L., Yao, L., Li, L., et al. (2020) · Cancer Control · doi:10.1177/1073274820902271 · Cited by 14
Huang, Z.-S., Wu, J., Li, Y., Lin, Y., & Li, X. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02240-3 · Cited by 14
Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
Yu, I. S., Aubin, F., Goodwin, R. A., Loree, J. M., Mather, C. A., Sheffield, B. S., Snow, S. L., & Gill, S. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221111705 · Cited by 17
Primary tumor location and survival in colorectal cancer: A retrospective cohort study
Aggarwal, H., Sheffield, K. M., Li, L., Lenis, D., Sorg, R. A., Barzi, A., & Miksad, R. A. (2020) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v12.i4.405 · Cited by 14
Xia, Y., Shan, G.-F., Yang, H., Zha, J., Wang, L., Chen, J., & Zhang, X. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109424 · Cited by 14
Miyamoto, Y., Akiyama, T., Kato, R., Sawayama, H., Ogawa, K., Yoshida, N., & Baba, H. (2022) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002392 · Cited by 14
Chen, Y., Liao, X., Li, Y., Cao, H., Zhang, F., Fei, B., Bao, C., Cao, H., Mao, Y., Chen, X., et al. (2023) · Trials · doi:10.1186/s13063-023-07137-y · Cited by 14
Progress of research on molecular targeted therapies for colorectal cancer
Huang, S., Ye, J., Gao, X., Huang, X., Huang, J., Lu, L., Lu, C., Li, Y., Luo, M., Xie, M., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1160949 · Cited by 13
Primary Tumor Sidedness as Prognostic and Predictive Biomarker in Metastatic Colorectal Cancer
Ciombor, K. K., & Goldberg, R. M. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3777 · Cited by 13
Shao, Y., Luo, Z., Yu, Y., He, Y., Liu, C., Chen, Q., Zhu, F., Nie, B., & Liu, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.939343 · Cited by 13
Prognostic Relevance of Primary Tumor Sidedness in Early-stage Colorectal Cancer
Ouchi, A., Sadachi, R., Hamaguchi, T., Tsukamoto, S., Shimada, Y., Inomata, M., Takii, Y., Komori, K., Shiomi, A., Shiozawa, M., et al. (2023) · Annals of Surgery · doi:10.1097/sla.0000000000006076 · Cited by 13
Li, D., Fu, Q., Li, M., Li, J., Yin, C., Zhao, J. H., & Li, F. (2017) · Future Oncology · doi:10.2217/fon-2016-0468 · Cited by 15
A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer
Capalbo, C., Belardinilli, F., Raimondo, D., Milanetti, E., Malapelle, U., Pisapia, P., Magri, V., Prete, A. A., Pecorari, S., Colella, M., et al. (2019) · Cancers · doi:10.3390/cancers11020147 · Cited by 13
Khawaja, H., Briggs, R., Latimer, C. H., Rassel, M., Griffin, D., Hanson, L., Bardelli, A., Di Nicolantonio, F., McDade, S. S., Scott, C. J., et al. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0301 · Cited by 12
“Although substantial advances have been made in the treatment of genetically defined subtypes, such as RAS/BRAF wild-type (4) and BRAFMT colorectal cancer (5), an effective therapeutic strategy for KRASMT colorectal cancer, the most common genetically defined subtype ( 40%–45%) is still lacking.”
BackgroundLee, S. F., Choi, C., Chan, S. K., Lam, K. O., Lee, V. H.-F., Wong, I. O.-L., & Chiang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.651299 · Cited by 12
Molecular Landscape and Therapeutic Strategies against Colorectal Cancer
Patel, A., & Gulhati, P. (2024) · Cancers · doi:10.3390/cancers16081551 · Cited by 12
Fiala, O., Ostašov, P., Hošek, P., Šorejs, O., Liška, V., Büchler, T., Poprach, A., Kučera, R., Topolčan, O., Šustr, J., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13761 · Cited by 12
Berger, M. D., Ning, Y., Stintzing, S., Heinemann, V., Cao, S., Zhang, W., Yang, D., Miyamoto, Y., Suenaga, M., Schirripa, M., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.02.048 · Cited by 12
Self-citationMetastatic colo-rectal cancer: real life experience from an Indian tertiary care center
Sharma, V., Sharma, A., Raina, V., Dabkara, D., Mohanti, B. K., Shukla, N. K., Pathy, S., Thulkar, S. P., Deo, S. V. S., Kumar, S., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08398-z · Cited by 12
ARHGAP25 expression in colorectal cancer as a biomarker associated with favorable prognosis
Zhang, Y., Lin, Y. H., Zhu, Y., Zhang, X., Li, T., & Yang, M. S. (2022) · Molecular and Clinical Oncology · doi:10.3892/mco.2022.2517 · Cited by 12
Merx, K., Martens, U. M., Kripp, M., Hoehler, T., Geißler, M., Gaiser, T., Mai, S., Kienle, P., Belle, S., Plöger, C., et al. (2017) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2017.06.2460 · Cited by 12
Xie, X., Zhou, Z., Song, Y., Wang, W., Dang, C., & Zhang, H. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4366 · Cited by 12
Ottaiano, A., Stefano, A. D., Capozzi, M., Nappi, A. G., Divitiis, C. D., Romano, C., Silvestro, L., Cassata, A., Casaretti, R., Tafuto, S., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00441 · Cited by 13
Metadata
- Authors
- Tejpar, S., Stintzing, S., Ciardiello, F., Tabernero, J., Van Cutsem, E., Beier, F., Esser, R., Lenz, H.-J., & Heinemann, V.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Ludwig-Maximilians-Universität München (DE)
- University of Campania "Luigi Vanvitelli" (IT)
- Universitat Autònoma de Barcelona (ES)
- Digestive Oncology, University Hospitals Leuven and KULeuven, Leuven, Belgium
- Merck KGaA, Darmstadt (Germany) (DE)
- University of Southern California (US)
- Corresponding author
- Tejpar, Sabine
- ORCID
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2017-02-01
- Volume
- 3
- Issue
- 2
- Pages
- 194
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC7505121
- OpenAlex
- W2531319683
- Cited by
- 709
- References
- 24
- Citations by year
- 2026: 19 · 2025: 35 · 2024: 64 · 2023: 48 · 2022: 70 · 2021: 89 · 2020: 85 · 2019: 97 · 2018: 102 · 2017: 96
- FWCI
- 53.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA Oncology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Funders
- National Cancer Institute (P30CA014089)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- metastatic colorectal cancer, RAS wild-type, primary tumor site, cetuximab, FOLFIRI, bevacizumab, first-line therapy, progression-free survival, overall survival, objective response rate, predictive biomarkers, CRYSTAL trial, FIRE-3 trial, EGFR inhibition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
